nach oben

Erschienen in:

25.09.2017 | Epidemiology

Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population

verfasst von: Ying L. Liu, Anurag Saraf, Benjamin Catanese, Shing M. Lee, Yuan Zhang, Eileen P. Connolly, Kevin Kalinsky

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Obesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups.

Methods

In a retrospective review, we identified 273 women with invasive BC administered Adriamycin/Taxane-based neoadjuvant chemotherapy from 2004 to 2016 with body mass index (BMI) data at diagnosis. Obesity was defined as BMI ≥30. Associations between obesity and event-free survival (EFS), using STEEP events, and overall survival (OS), using all-cause mortality, were assessed overall and stratified by tumor subtype [[Hormone Receptor Positive (HR+)/HER2−, HER2+, and Triple-Negative Breast Cancer (TNBC])] in our diverse population.

Results

Median follow-up was 32.6 months (range 5.7–137.8 months). Overall, obesity was associated with worse EFS (HR 1.71, 95% CI 1.03–2.84, p = 0.04) and a trend towards worse OS (p = 0.13). In HR+/HER2− disease (n = 135), there was an interaction between obesity and hormonal therapy with respect to OS but not EFS. In those receiving tamoxifen (n = 33), obesity was associated with worse OS (HR 9.27, 95% CI 0.96–89.3, p = 0.05). In those receiving an aromatase inhibitor (n = 89), there was no association between obesity and OS. In TNBC (n = 44), obesity was associated with worse EFS (HR 2.62, 95% CI 1.03–6.66, p = 0.04) and a trend towards worse OS (p = 0.06). In HER2+ disease (n = 94), obesity was associated with a trend towards worse EFS (HR 3.37, 95% CI 0.97–11.72, p = 0.06) but not OS. Race/ethnicity was not associated with survival in any subtype, and there were no interactions with obesity on survival.

Conclusions

Obesity may negatively impact survival, with differences among tumor subtypes.

Nur mit Berechtigung zugänglich

Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384(9945):755–765CrossRefPubMedPubMedCentral

Tsai AG, Williamson DF, Glick HA (2011) Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obesity Rev 12(1):50–61CrossRef

Gathirua-Mwangi WG, Zollinger TW, Murage MJ, Pradhan KR, Champion VL (2015) Adult BMI change and risk of breast cancer: National Health and Nutrition Examination Survey (NHANES) 2005–2010. Breast Cancer 22(6):648–656CrossRefPubMedPubMedCentral

Jiralerspong S, Goodwin PJ (2016) Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol 34(35):4203–4216CrossRefPubMed

Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914CrossRefPubMedPubMedCentral

Niraula S, Ocana A, Ennis M, Goodwin PJ (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134(2):769–781CrossRefPubMed

Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627–635CrossRefPubMed

Allott EH, Hursting SD (2015) Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer 22(6):R365–R386CrossRefPubMedPubMedCentral

Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653–2659CrossRefPubMed

10.

Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415CrossRefPubMed

11.

Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476CrossRefPubMedPubMedCentral

12.

Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118(23):5937–5946CrossRefPubMedPubMedCentral

13.

Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA (2013) Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer 119(13):2447–2454CrossRefPubMedPubMedCentral

14.

Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM (2015) Overweight as a prognostic factor for triple-negative breast cancers in chinese women. PLoS ONE 10(6):e0129741CrossRefPubMedPubMedCentral

15.

Mazzarella L, Disalvatore D, Bagnardi V et al (2013) Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer 49(17):3588–3597CrossRefPubMed

16.

Widschwendter P, Friedl TW, Schwentner L et al (2015) The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 17:129CrossRefPubMedPubMedCentral

17.

Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307(5):491–497CrossRefPubMed

18.

Bandera EV, Maskarinec G, Romieu I, John EM (2015) Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. Adv. Nutr. 6(6):803–819CrossRefPubMedPubMedCentral

19.

Hunt BR, Hurlbert MS (2016) Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005–2014. Cancer epidemiology. 45:169–173CrossRefPubMed

20.

Tichy JR, Deal AM, Anders CK, Reeder-Hayes K, Carey LA (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150(3):667–674CrossRefPubMedPubMedCentral

21.

Warner ET, Ballman KV, Strand C et al (2016) Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat 159(1):109–118CrossRefPubMedPubMedCentral

22.

Hall IJ, Newman B, Millikan RC, Moorman PG (2000) Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 151(8):754–764CrossRefPubMed

23.

Karatas F, Erdem GU, Sahin S et al (2016) Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Breast 32:237–244CrossRefPubMed

24.

Fontanella C, Lederer B, Gade S et al (2015) Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 150(1):127–139CrossRefPubMed

25.

Erbes T, Stickeler E, Rucker G et al (2016) BMI and pathologic complete response to neoadjuvant chemotherapy in breast cancer: a study and meta-analysis. Clin Breast Cancer 16(4):e119–e132CrossRefPubMed

26.

WHO (1995) Physical status: the use and interpretation of anthropometry. WHO, Geneva

27.

Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5(5):303–311 discussion 312–303 PubMed

28.

Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract/Am Soc Clin Oncol 6(4):195–197CrossRef

29.

Tchrakian N, Flanagan L, Harford J, Gannon JM, Quinn CM (2015) New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers. Virchows Archiv 468:207–211CrossRefPubMed

30.

Zhang C, Wang S, Israel HP et al (2015) Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. SpringerPlus 4:386CrossRefPubMedPubMedCentral

31.

Hudis CA, Barlow WE, Costantino JP et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127–2132CrossRefPubMed

32.

Luen SJ, Salgado R, Fox S et al (2017) Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18(1):52–62CrossRefPubMed

33.

Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791CrossRefPubMedPubMedCentral

34.

Matthews SB, Thompson HJ (2016) The obesity-breast cancer conundrum: an analysis of the issues. Int J Mol Sci 17(6):989CrossRefPubMedCentral

35.

Renehan AG, Zwahlen M, Egger M (2015) Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15(8):484–498CrossRefPubMed

36.

Ford NA, Lashinger LM, Allott EH, Hursting SD (2013) Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link. Front Oncol 3:209CrossRefPubMedPubMedCentral

37.

Lashinger LM, Ford NA, Hursting SD (2014) Interacting inflammatory and growth factor signals underlie the obesity-cancer link. J Nutr 144(2):109–113CrossRefPubMed

38.

Hair BY, Troester MA, Edmiston SN et al (2015) Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors. Cancer Epidemiol Biomark Prevent 24(3):580–586CrossRef

39.

Rossi EL, de Angel RE, Bowers LW et al (2016) Obesity-associated alterations in inflammation, epigenetics, and mammary tumor growth persist in formerly obese mice. Cancer Prevent Res 9(5):339–348CrossRef

40.

Goodwin PJ (2013) Obesity and endocrine therapy: host factors and breast cancer outcome. Breast 22(Suppl2):S44–S47CrossRefPubMed

41.

Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30(32):3967–3975CrossRefPubMedPubMedCentral

42.

Subbaramaiah K, Howe LR, Bhardwaj P et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevent Res 4(3):329–346CrossRef

43.

Hubalek M, Oberguggenberger A, Beer B et al (2014) Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. Clin Breast Cancer 14(4):291–296CrossRefPubMed

44.

Diorio C, Lemieux J, Provencher L, Hogue JC, Vachon E (2012) Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Res Treat 136(2):573–579CrossRefPubMed

45.

Sini V, Lunardi G, Cirillo M et al (2014) Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. Br J Cancer 110(5):1133–1138CrossRefPubMedPubMedCentral

46.

Phipps AI, Ichikawa L, Bowles EJA et al (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60–66CrossRefPubMedPubMedCentral

47.

George SM, Bernstein L, Smith AW et al (2014) Central adiposity after breast cancer diagnosis is related to mortality in the health, eating, activity, and lifestyle study. Breast Cancer Res Treat 146(3):647–655CrossRefPubMed

48.

Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA (2015) Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. Cancer Causes Control 26(12):1803–1811CrossRefPubMedPubMedCentral

49.

Liu YL, Saraf A, Catanese B et al (2017) Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. Breast Cancer Res Treat. doi:10.1007/s10549-017-4507-y

Titel: Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population
verfasst von: Ying L. Liu
Anurag Saraf
Benjamin Catanese
Shing M. Lee
Yuan Zhang
Eileen P. Connolly
Kevin Kalinsky
Publikationsdatum: 25.09.2017
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4507-y

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population